]> 2026-07-31T11:52:03+00:00 WBR0392 0 en Tenofovir + emtricitabine + abacavir This combination has 3 NRTIs, a combination that is usually not recommended. Darunavir + raltegravir + lamivudine This combination has only 1 NRTI, which is usually not recommended. Darunavir is a protease inhibitor and raltegravir is an integrase inhibitor. Efavirenz + tenofovir + nevirapine This combination has only 1 NRTI, which is is usually not recommended. Efavirenz and nevirapine are both NNRTIs. Ritonavir + tenofovir + lopinavir This combination has only 1 NRTI. Ritonavir and lopinavir are both protease inhibitors. Raltegravir + tenofovir + emtricitabine This combination is most suitable because it includes 2 NRTIs (tenofovir + emtricitabine) and 1 integrase inhibitor. Pharmacology A 35-year-old HIV-positive man presents to the infectious disease clinic for a routine follow-up. His most recent CD4 count 3 months ago was 670 cells/mm3 and his viral load was low to undetectable. At the time, the physician did not initiate high active antiretroviral therapy (HAART). Over the past month, the patient had been admitted twice to the hospital for a community-acquired pneumonia and for a gastroenteritis. His current lab results are remarkable for a CD4 of 231 cells/mm3 and a viral load of 325,000 copies/ml. Given his current lab findings, the infectious disease physician decides to initiate HAART for this patient. Which of the following drug combinations is most suitable for this patient? E Infectious Disease 2020-10-28T00:25:43Z 2459150.5178588 WBR0392